secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ultragenyx Pharmaceutical Inc. (RARE)
CIK:        0001515673
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0000950170-25-103026
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ultragenyx Q2 revenue $166M (+13% YoY); net loss narrows; UX111 BLA receives CRL
--------------------------------------------------------------------------------

- Q2 total revenue $166M, Crysvita $120M, Dojolvi $23M; net loss $115M ($1.17/sh) vs $132M loss prior year.
- Reaffirms 2025 guidance: total rev $640-670M, Crysvita $460-480M, Dojolvi $90-100M; path to profitability in 2027.
- UX111 gene therapy for Sanfilippo type A received FDA CRL for CMC/manufacturing issues; clinical data package no issues; resubmission after Type A meeting.
- GTX-102 for Angelman syndrome granted Breakthrough Therapy; Phase 3 Aspire fully enrolled (129 pts); data expected H2 2026.
- UX143 Phase 3 final analysis expected end of 2025; DTX401 BLA submission planned Q4 2025; cash $539M as of June 30.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1515673/000095017025103026/0000950170-25-103026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1515673/000095017025103026/rare-20250805.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-103026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer